Brazilian researcher who helped country's grain boom wins World Food Prize
By Marcelo Teixeira
NEW YORK (Reuters) - Brazilian microbiologist Mariangela Hungria, whose research has helped farmers in the country sharply boost grain production, has been named the 2025 World Food Prize Laureate, the Iowa-based foundation organizing the prize said on Tuesday.
Hungria has been a researcher for more than 40 years at Brazil's state-run agricultural center Embrapa, where she works on seeds and soil treatments that enable plants to source nutrients through soil bacteria, a particularly important development for soybean crops.
Her work helped Brazil increase soybean production from around 15 million metric tons in the 1980s to more than 170 million tons today, making the country the world's largest producer and exporter of the commodity.
"I was always interested in making viable the use of biological materials in commercial agriculture," Hungria told Reuters.
Good soybean growth requires a lot of nitrogen for the plant, but relying on nitrogen-based chemical fertilizers was expensive for Brazilian farmers and meant the country was heavily dependent on imported fertilizers, she said.
Hungria isolated strains of a soil bacteria named rhizobia and developed a way to inoculate it in the soybean seeds used in Brazil. The strains helped the soy plants extract more nitrogen from the soil, boosting their growth.
The solution has since become widespread and is used in more than 40 million hectares of Brazil's roughly 48 million hectares of soy plantations.
Hungria also developed other biological solutions, including using strains of Azospirillum brasilense bacteria to boost the size of roots on crops such as corn, allowing the plants to reach deeper for humidity or nutrients.
The use of biological products in agriculture has grown quickly in recent years, as consumers increasingly demand food produced with fewer chemicals.
The researcher will receive $500,000 for being named a Laureate. The World Food Prize was created by Norman E. Borlaug, an American agronomist who developed solutions to increase agricultural production.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Insider
4 hours ago
- Business Insider
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
ZUG, Switzerland and BOSTON, May 29, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the following investor conferences in June. William Blair's 45 th Annual Growth Stock Conference Date: Tuesday, June 3, 2025 Time: 11:20 a.m. CT Goldman Sachs' 46 th Annual Global Healthcare Conference Date: Monday, June 9, 2025 Time: 3:20 p.m. ET A live webcast will be available on the "Events & Presentations" page in the Investors section of the Company's website at A replay of the webcasts will be archived on the Company's website for 14 days following the presentation. About CRISPR Therapeutics Since its inception over a decade ago, CRISPR Therapeutics has evolved from a research-stage company advancing gene editing programs into a leader that celebrated the historic approval of the first-ever CRISPR-based therapy. The Company has a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases. In 2018, CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic to investigate the treatment of sickle cell disease and transfusion-dependent beta thalassemia. Beginning in late 2023, CASGEVY ® (exagamglogene autotemcel [exa-cel]) was approved in several countries to treat eligible patients with either of these conditions. The Nobel Prize-winning CRISPR technology has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines. To accelerate and expand its efforts, CRISPR Therapeutics has formed strategic partnerships with leading companies including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California. To learn more, visit


Business Wire
5 hours ago
- Business Wire
Iksuda Therapeutics announces first patient successfully dosed in phase 1 trial evaluating IKS03 in advanced B cell non-Hodgkin lymphomas
NEWCASTLE, England--(BUSINESS WIRE)--Iksuda Therapeutics (Iksuda), the developer of class-leading antibody drug conjugates (ADCs) with clinically validated tumour-selective payload release formats, today announces the completion of dosing of its first patient with IKS03, a CD19-directed ADC, in a phase 1, first-in-human, clinical trial in patients with advanced B cell non-Hodgkin lymphoma. This first-in-human study ( will evaluate the safety, tolerability, preliminary antineoplastic activity, pharmacokinetics and pharmacodynamics of increasing dose levels of IKS03, and determine the recommended dose for dose-expansion. Efficacy will be further evaluated in disease-specific expansion cohorts. The study is currently enrolling patients across clinical sites in Italy, Spain, Australia, United States and Canada. Dr Dave Simpson, Chief Executive Officer, Iksuda Therapeutics, said: 'With the first patient successfully completing the safety evaluation period with IKS03, Iksuda demonstrates its continued commitment to drive its differentiated ADCs through clinical proof of concept, further solidifying our position as a clinical-stage ADC-focused company. Although there have been advances in the treatment of non-Hodgkin lymphoma in recent years, there remains a significant unmet patient need, and we hope that IKS03 will be able to build on the potential benefit-risk profile suggested by the data generated in preclinical studies.' About IKS03 IKS03 is a best-in-class CD19-targeting ADC delivering a tumour-activated prodrug pyrrolobenzodiazepine (PBD) which was licensed from LigaChem Biosciences (formerly LegoChem Biosciences) ( Preclinical testing demonstrates best-in-class efficacy (vs in-clinic and marketed CD19-targeted therapies) in in vivo xenograft models and significantly raised maximum tolerated dose (MTD) in non-human primate disease models, demonstrating its potential to be the leading anti-CD19 therapy in B-cell cancers. About Iksuda Therapeutics: Iksuda Therapeutics is a clinical stage, UK-based biotechnology company focussed on the development of class leading antibody drug conjugates (ADCs) targeting difficult-to-treat haematological and solid tumours. Iksuda's pipeline of ADCs is centred on a portfolio of prodrug DNA and protein alkylating payloads in combination with stable conjugation chemistries including its proprietary PermaLink ® platform. The Company's design concepts for ADCs are now clinically validated to significantly improve the therapeutic index of this important modality and improve the outcomes for patients living with cancer.
Yahoo
9 hours ago
- Yahoo
Musk aiming to send uncrewed Starship to Mars by end of 2026
By Steve Gorman and Joey Roulette LOS ANGELES (Reuters) -Two days after the latest in a string of test-flight setbacks for his big new Mars spacecraft, Starship, Elon Musk said on Thursday he foresees the futuristic vehicle making its first uncrewed voyage to the red planet at the end of next year. Musk presented a detailed Starship development timeline in a video posted online by his Los Angeles area-based rocket company, SpaceX, a day after saying he was departing the administration of U.S. President Donald Trump as head of a tumultuous campaign to slash government bureaucracy. The billionaire entrepreneur had said earlier that he was planning to scale back his role in government to focus greater attention on his various businesses, including SpaceX and electric car and battery maker Tesla Inc. Musk acknowledged that his latest timeline for reaching Mars hinged on whether Starship can accomplish a number of challenging technical feats during its flight-test development, particularly a post-launch refueling maneuver in Earth orbit. The end of 2026 would coincide with a slim window that occurs once every two years when Mars and Earth align around the sun for the closest trip between the two planets, which would take seven to nine months to transit by spacecraft. Musk gave his company a 50-50 chance of meeting that deadline. If Starship were not ready by that time, SpaceX would wait another two years before trying again, Musk suggested in the video. The first flight to Mars would carry a simulated crew consisting of one or more robots of the Tesla-built humanoid Optimus design, with the first human crews following in the second or third landings. Musk said he envisioned eventually launching 1,000 to 2,000 ships to Mars every two years to quickly establish a self-sustaining permanent human settlement. NASA is currently aiming to return humans to the surface of the moon aboard Starship as early as 2027 - more than 50 years after its last manned lunar landings of the Apollo era - as a stepping stone toward ultimately launching astronauts to Mars sometime in the 2030s. Musk, who has advocated for a more Mars-focused human spaceflight program, has previously said he was aiming to send an unmanned SpaceX vehicle to the red planet as early as 2018 and was targeting 2024 to launch a first crewed mission there. The SpaceX founder was scheduled to deliver a livestream presentation billed as "The Road to Making Life Multiplanetary" from the company's Starbase, Texas, launch site on Tuesday night, following a ninth test flight of Starship that evening. But the webcast was canceled without notice after Starship spun out of control and disintegrated in a fireball about 30 minutes after launch and roughly halfway through its flight path without achieving some of its most important test goals. Two preceding test flights in January and March failed in more spectacular fashion, with the spacecraft blowing to pieces on ascent moments after liftoff, raining debris over parts of the Caribbean and forcing scores of commercial jetliners to change course as a precaution. Musk shrugged off the latest mishap on Tuesday with a brief post on X, saying it produced a lot of "good data to review" and promising a faster launch "cadence" for the next several test flights.